Orioles reliever Keegan Akin to miss season after Tommy John surgery

Lede

Right‑handed reliever Keegan Akin underwent Tommy John surgery on his right elbow on Wednesday, sealing his season for the Baltimore Orioles and likely sidelining him well into the 2025 campaign. The procedure, announced by the club’s medical staff, adds a major void to a bullpen already grappling with injuries.

Core developments

The Orioles confirmed that Akin, 28, had surgery to repair a torn ulnar collateral ligament (UCL) in his right elbow. The operation was performed by the team’s orthopedic surgeon at Johns Hopkins Hospital, the same facility that has treated several Baltimore pitchers in recent years. Camden Chat reported that the club expects a typical recovery timeline of 12 to 15 months for a pitcher returning from Tommy John.

Akin entered the 2024 season as a middle‑relief option, appearing in 27 games before the injury. He posted a 3.86 earned run average (ERA) over 30.1 innings, striking out 31 batters while walking 12. Those numbers, cited by MLB Trade Rumors, illustrate his role as a dependable swing‑man who could be called upon in high‑leverage situations.

The Orioles placed Akin on the 60‑day injured list immediately after the surgery, freeing a roster spot for a call‑up from Triple‑A Norfolk. Yahoo Sports noted that the team added right‑hander John Schreiber to the active roster to help fill the gap in the late‑inning bullpen.

Team officials released a brief statement emphasizing Akin’s “positive attitude” during the rehabilitation process and expressing confidence in his long‑term health. Baltimore Sun quoted the club’s director of player development, saying the organization will “support Keegan every step of the way as he works toward a full recovery.”

Media outlets such as NBC Sports and CBS Sports echoed the sentiment, highlighting the surgery as a “standard procedure for pitchers” and noting that many athletes return to their pre‑injury level of performance after a full rehab cycle.

Why it matters

Tommy John surgery has become a rite of passage for many modern pitchers, but each case reshapes a team's immediate strategic calculus. For Baltimore, Akin’s absence reduces the depth of a bullpen that has already been shuffled by the loss of starter Dean Kremer to a shoulder strain and the placement of reliever Pedro Avila on the 10‑day IL earlier this month.

The Orioles entered the season with a 4‑3‑1 bullpen composition: a closer, two set‑up men, and three swing‑men. Akin filled the swing‑man role, often bridging the gap between middle relief and late‑inning work. His removal forces manager Brandon Hyde to rely more heavily on younger arms from Norfolk, such as left‑hander James McCarthy, who has yet to pitch more than 15 innings at the major‑league level.

From a financial perspective, Akin is under team control through the 2026 season, with a modest salary that fits the Orioles’ cost‑conscious model. His long‑term health will affect whether Baltimore can retain a cost‑effective, middle‑relief piece or be forced to explore trade options once he is cleared to play.

Historically, pitchers who undergo Tommy John surgery return after roughly a year, but the quality of that return varies. A 2022 analysis by the American Sports Medicine Institute, referenced in RotoWire, found that 84 % of MLB pitchers who returned were able to pitch at the same or higher innings total the following season, but only 57 % matched their pre‑injury ERA. The Orioles’ medical staff will likely tailor Akin’s rehab to prioritize arm strength and command before throwing his full repertoire.

Differing viewpoints and reactions

While the club’s official tone remained optimistic, analysts offered a range of perspectives. MLB Trade Rumors suggested that Akin’s injury could make him a “potential trade chip” if he returns to form, as teams with bullpen deficiencies might be willing to part with prospects for a proven right‑hander. Conversely, RotoWire warned that “any pitcher coming off a UCL reconstruction carries inherent risk,” advising fantasy owners to be cautious about drafting Akin in early rounds for the 2025 season.

Former Orioles pitcher and current ESPN analyst, Ryan O’Hearn, told Camden Chat that “the team has a solid plan for the bullpen, but losing a guy like Keegan changes the day‑to‑day decisions for Brandon Hyde.” He emphasized that Hyde will need to manage workload carefully to avoid overtaxing the remaining arms.

Fans expressed a mixture of sympathy and frustration on social media. A popular Orioles fan forum thread highlighted Akin’s “work ethic” and hoped for a “full comeback,” while another user pointed out that the team’s “depth chart looks thin” and urged the front office to consider a mid‑season acquisition.

What’s next

Akin will begin a structured rehabilitation program that typically starts with a period of immobilization, followed by passive range‑of‑motion exercises, progressive throwing, and finally bullpen sessions. The Orioles’ medical staff expects him to start light throwing in about six weeks and potentially rejoin a simulated game environment by the start of the 2025 spring training.

In the short term, Baltimore will rely on a blend of veterans and prospects to maintain bullpen stability. The club has already promoted right‑hander Jake McCarthy from Norfolk and is reportedly in talks with free‑agent reliever Trevor Rosenthal as a low‑risk, short‑term addition.

Long‑term, the organization will reassess Akin’s role once he is medically cleared. If he regains his pre‑injury velocity (averaging 94 mph in 2024, per Yahoo Sports) and command, he could return to the swing‑man slot and provide the flexibility Hyde values. If recovery lags, the Orioles may explore a trade to recoup value before his contract expires.

For now, the Orioles’ focus remains on supporting Akin’s rehab and shoring up a bullpen that has been a cornerstone of the team’s recent competitive resurgence.